Related Link: The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight Why It's Important: The production handicap bodes ill for Novavax, especially as others such as BioNTech SE BNTX, Pfizer Inc. PFE and Moderna Inc MRNA have scaled up and are distributing their vaccines across the globe in full swing. Novavax has a lot to do to catch up, despite its vaccine differentiating itself from the already available vaccines in the market by its logistical advantage and proven efficacy against variant strains of the virus. NVAX Price Action: On Tuesday morning, Novavax shares were rallying 11.89% to $196.53, reacting to the negative news flow on Johnson & Johnson's JNJ vaccine. Related Link: Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates (Photo: Novavax)